A Phase I, Open Label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Effect of Steady-state TMC278 on the Pharmacokinetics of a Single Dose of Digoxin.
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Rilpivirine (Primary) ; Digoxin
- Indications Atrial fibrillation; Atrial flutter; Heart failure; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 13 Jul 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2011-004159-38).
- 29 Jun 2012 Company changed from Tibotec Pharmaceuticals Ireland to Janssen R&D Ireland as reported by ClinicalTrials.gov.
- 29 Jun 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History